Weight and Metabolic Health

Three tests decide most of what follows: A1C, fasting glucose, and the two-hour glucose tolerance test. A1C is the one most people get, and it carries a trap for Black families. Sickle cell trait, carried by about 1 in 13 Black Americans, and G6PD deficiency both make A1C read lower than your blood sugar actually runs, so a normal-looking result can hide prediabetes or diabetes.

If either runs in your family, ask for a fasting glucose or a tolerance test alongside the A1C. Our A1C chart converts each number to an average blood sugar and explains the two traits; the prediabetes guide covers the window where lifestyle change still returns the numbers to normal, which the Diabetes Prevention Program showed cuts the risk of diabetes by more than half.

Yes, they work. Across the SUSTAIN and STEP trials, semaglutide lowered blood sugar and body weight similarly in Black and other participants, and a post hoc analysis by race and ethnicity found the same. Tirzepatide, which acts on two gut hormones rather than one, drove more weight loss than semaglutide head to head in SURMOUNT-5: 20.2 percent against 13.7 percent at 72 weeks.

That trial also enrolled Black participants at 19 percent, far more than the semaglutide trials managed, though still too few to test for race-specific differences. Nothing in the data gives a race-specific reason to pick one drug over the other.

The deciders are your diabetes status, your insurance, the side effects you can live with, and whether a brand product is available to you at all. The same boxed warning applies to both: a personal or family history of medullary thyroid carcinoma rules them out.

Coverage changed more in the last year than in the five before it. Since July 1, 2026, Medicare has a flat $50-a-month pathway for covered GLP-1s through December 31, 2027, with no sign-up: your prescriber writes the script, the pharmacy bills it, and the first claim is denied on purpose to start the paperwork. Part D already covers GLP-1s prescribed for type 2 diabetes, moderate to severe sleep apnea, and MASH, so the indication on the prescription decides everything.

Thirteen state Medicaid programs covered the obesity indication as of January 2026, and a federal model lets more states join at negotiated prices. Paying cash, Lilly's own price for Zepbound runs $299 to $449 a month and Novo's Wegovy runs $199 to $349, with a $149 pill option. Maryland's affordability board set the first state GLP-1 price cap, $274 a month for Ozempic, but it binds only state and local government employee plans.

For the rules in your state, start with our online GLP-1 prescription guide by state, which covers each state's Medicaid stance and the licensed telehealth options, and our ranked comparison of online GLP-1 prescribers.

Weight rarely arrives alone. Insulin resistance shows up as belly weight that won't move and, in many Black women, as PCOS. Metabolic syndrome is the formal cluster, and its standard scoring under-counts Black adults because it leans on triglycerides and HDL, which tend to run closer to normal in Black patients even when blood pressure and waist size are high.

Fatty liver disease, now called MASLD, has the lowest measured prevalence in Black Americans, largely because the fat-promoting PNPLA3 gene variant is rarer in people of African ancestry; that's a real finding, not immunity, and the risk factors still apply. Sleep apnea is the one most often missed: in the all-Black Jackson Heart Sleep Study, about 24 percent of participants had moderate to severe apnea and only 5 percent of those cases had ever been diagnosed. And rapid weight loss on a GLP-1 is itself a known cause of gallstones.

The damage diabetes does is mostly preventable and mostly silent until it isn't. A yearly dilated eye exam catches retinopathy while it can still be treated. Daily foot checks and a podiatrist on your care team are what stand between a small ulcer and an amputation: in the landmark pathway study, 84 percent of diabetic limb amputations followed an ulcer that began with minor trauma, and only 23.6 percent of Black Medicare patients had any attempt to restore blood flow in the two years before their leg amputation.

Before signing an amputation consent, ask for a toe pressure or ABI and a vascular surgery consult. Numbness or tingling in both feet is diabetic neuropathy until proven otherwise, though B12 deficiency, nerve compression and an underactive thyroid can cause it too, and several of those are reversible. On darker skin, redness is an unreliable sign, so judge a wound by warmth, swelling, drainage and odor; our guide shows what diabetic skin changes look like on dark skin.

Primary care can diagnose and treat most of what is on this page, including starting a GLP-1. An endocrinologist is the specialist for diabetes that is hard to control, for thyroid questions, and for metabolic disease that is not responding. A registered dietitian turns a diagnosis into meals you'll actually eat, and Medicare Part B covers medical nutrition therapy for diabetes at no cost with a doctor's referral.

A podiatrist belongs on the team of anyone with diabetes and any foot change. Our directory lists Black clinicians who self-identify and are license-verified: endocrinologists, registered dietitians, primary care and podiatrists.

Every figure above was read from its primary source on the date this hub was last reviewed: the CDC obesity and diabetes reports and the trial papers by PubMed ID. We don't quote a number we couldn't open ourselves, and we say when a trial was too small or too unrepresentative to answer a question for Black patients. The guides linked here are written by the Black Health editorial team and reviewed by our medical editorial board; each carries its own sources.

If you find an error, tell us and we'll correct it in the open. Last reviewed October 21, 2026.